Denoeud Ndam Lise auteur aut IRD Clément M. C. auteur aut IRD Briand Valérie auteur aut IRD Akakpo J. auteur aut IRD Agossou V. K. auteur aut IRD Atadokpédé F. auteur aut IRD Dossou-Gbété L. auteur aut IRD Komongui D. G. auteur aut IRD Afangnihoun A. auteur aut IRD Girard P. M. auteur aut IRD Zannou D. M. auteur aut IRD Cot Michel auteur aut IRD text journalArticle eng text/pdf born digital access Objective: To investigate the tolerability of mefloquine intermittent preventive treatment (MQ IPTp) for malaria in HIV-infected pregnant women compared with HIV-negative women. Design: Prospective cohort study comparing samples of HIV-negative and HIV- infected pregnant women from 2 clinical trials conducted in Benin. Methods: One hundred and three HIV-infected women from the ongoing PACOME trial were compared with 421 HIV-negative women from a former trial, both trials aiming to evaluate the efficacy and tolerability of MQ IPTp, administered at the dose of 15 mg/kg. Descriptive analysis compared the proportion of women reporting at least 1 adverse reaction, according to HIV status. Multilevel logistic regression identified factors associated with the probability of reporting an adverse reaction for each MQ intake. Results: Dizziness and vomiting were the most frequent adverse reactions. Adverse reactions were less frequent in HIV-infected women (65% versus 78%, P = 0.009). In multilevel analysis, HIV infection [odds ratio (OR) = 0.23, 95% confidence interval (CI) = 0.08 to 0.61] decreased the risk for adverse reactions, whereas detectable viral load (OR = 2.46, 95% CI = 1.07 to 5.66), first intake (versus further intakes, OR = 5.26, 95% CI = 3.70 to 7.14), older age (OR = 1.62, 95% CI = 1.13 to 2.32), and higher education level (OR = 1.71, 95% CI = 1.12 to 2.61) increased the risk. Moderate and severe adverse reactions were more frequent when antiretrovirals were started concomitantly with a MQ intake. Conclusions: This study provides reassuring data on the use of MQ IPTp in HIV-infected pregnant women. However frequent, adverse reactions remained moderate and did not impair adherence to MQ IPTp. In this high-risk group, MQ might be an acceptable alternative in case sulfadoxine-pyrimethamine loses its efficacy for intermittent preventive treatment. specialized HIV malaria pregnancy mefloquine drug tolerance Benin 052 050 61 1 64-72 2012 1525-4135 https://www.documentation.ird.fr/hor/fdi:010057157 10.1097/QAI.0b013e3182615a58 1525-4135 [F B010057157] https://www.documentation.ird.fr/hor/fdi:010057157 https://www.documentation.ird.fr/intranet/publi/2012/09/010057157.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2012-10-03 2017-08-23 fdi:010057157 fre